Tendinopathy Annual Evaluation Checklist: A Complete Management Guide

What tendinopathy annual evaluation is actually for

Tendinopathy reflects a failed healing response inside the tendon: collagen becomes disorganized, ground substance increases, and small blood vessels grow into tissue that is normally relatively avascular. This is a structural and biological picture (tendinosis), distinct from acute inflammatory tendinitis, and that distinction is why anti-inflammatory approaches alone are not the mainstay of treatment.

The natural history is not a straight line. A patient who is pain-free at six months can be back to loading beyond the tendon's current capacity by month twelve, quietly re-accumulating tissue stress before pain returns. Relapse after apparent recovery is widely reported in the tendinopathy literature, though published recurrence rates vary considerably depending on tendon site, follow-up length, and how "recurrence" is defined, so a single precise percentage should be treated cautiously rather than quoted as a fixed statistic. The purpose of a structured annual review is to catch that silent regression while the patient is still engaged in care, rather than after they have quietly abandoned a loading program.

A tendinopathy annual review should combine a validated pain and function score (VISA-A, VISA-P, DASH, or PRTEE), a load-tolerance and limb-symmetry check, a review of any injections or off-label agents used in the past year, and a red-flag screen; a drop of roughly 10 or more points on a VISA score from the prior year, or a limb-symmetry deficit greater than about 15 percent, is a reasonable trigger to re-open the loading program and rule out relapse rather than waiting for the next scheduled visit. This framing follows general rehabilitation and sports medicine practice around VISA-based monitoring and load management; exact numeric thresholds differ between guidelines and should be confirmed against current clinical protocols before being applied as a rigid rule.

Who this checklist is for

Anyone with a confirmed diagnosis of tendinopathy at the Achilles, patellar tendon, rotator cuff, or lateral epicondyle benefits from a structured annual review. Patients who have had corticosteroid injections, platelet-rich plasma (PRP), or off-label peptide protocols such as BPC-157 need additional documentation of that history at each yearly visit, both to track whether the intervention worked and to watch for delayed safety signals.

Step 1: Pain and functional outcome scoring

VISA scores

The Victorian Institute of Sport Assessment (VISA) questionnaires are the standard patient-reported outcome tools in tendinopathy research and clinical follow-up. VISA-A is used for Achilles tendinopathy and VISA-P for patellar tendinopathy, each scored out of 100, with 100 representing full, pain-free function. These tools were developed and validated specifically to give a reproducible year-over-year comparison that a clinician's impression alone cannot provide.

For the shoulder and elbow, the DASH (Disabilities of the Arm, Shoulder and Hand) questionnaire and the Patient-Rated Tennis Elbow Evaluation (PRTEE) are the equivalent instruments.

At annual review, a meaningful drop in VISA (commonly cited as roughly 10 points or more compared with the prior visit) is a reasonable signal to re-examine the loading program and look for a precipitating change in activity, rather than assuming normal variability.

Activity-related pain (VAS)

Alongside a VISA score, record a Visual Analogue Scale (VAS) pain rating during a standard provocation test: the single-leg heel rise for the Achilles, and the single-leg decline squat for the patellar tendon, which is generally considered a higher-strain, more sensitive test than a flat-surface squat. As a general clinical guide, post-activity pain of 0 to 2 out of 10 is usually considered acceptable, 3 to 5 suggests load should be reduced, and above 5 suggests the current program is provoking pathological load and needs modification. These bands are commonly used in clinical practice rather than fixed by a single regulatory or guideline body, and individual programs may set different cutoffs.

Step 2: Load tolerance and exercise program audit

Load management is the most consistently supported intervention across tendinopathy sites. The annual review should establish whether the patient is progressing appropriately or has plateaued.

Loading protocols

The Alfredson eccentric calf-loading protocol and heavy slow resistance (HSR) training are the two most widely studied structured programs for Achilles tendinopathy, and multiple trials have reported that both approaches can produce clinically meaningful improvement in VISA-A scores over roughly 12 weeks. Exact point improvements differ between studies and should be verified against the primary trial reports rather than treated as a universal constant. At annual review, document which program the patient is on, for how long, and whether their VISA score has moved.

If a patient has been on an unchanged program for more than about 16 weeks without measurable VISA improvement, restructuring the program before the next annual visit is reasonable, rather than continuing an approach that is not working.

Limb symmetry testing

Strength deficits between the affected and unaffected side are a practical surrogate for tendon loading capacity. The Limb Symmetry Index (LSI) compares single-leg task performance between limbs; a return-to-sport threshold around 90 percent LSI on heel-rise endurance testing is commonly cited in rehabilitation practice, though this figure comes from clinical convention as much as from a single definitive trial.

At annual review, record:

• Maximum single-leg heel-rise repetitions (Achilles)
• Single-leg squat depth in pain-free range (patellar)
• Shoulder abduction peak force via handheld dynamometry (rotator cuff)

Flag any side-to-side deficit greater than roughly 15 percent for targeted strengthening before the next review.

Training and activity history

Tendinopathy is, at its core, a mismatch between tendon capacity and the load placed on it. Ask directly about changes in training volume, frequency, or occupational repetitive strain over the past 12 months. Rapid increases in running mileage or repetitive court-sport loading are commonly implicated precipitants of relapse in the sports medicine literature, and gradual, monitored progression is the standard general recommendation, though a single universal "safe percentage increase" threshold is not firmly established across all populations.

Step 3: Imaging review

Imaging in tendinopathy is confirmatory, not diagnostic. Pain and functional scores should drive treatment decisions; ultrasound and MRI findings provide supporting context and do not reliably track with symptoms.

Ultrasound

Greyscale ultrasound can show tendon hypoechogenicity (matrix disorganization), thickening, intrasubstance tears, and calcification. Power Doppler can detect neovascularization, which is thought to relate to the nerve ingrowth implicated in tendinopathy pain. It is well established in the tendon imaging literature that structural change on ultrasound and symptom change do not move in lockstep, so a stable-looking tendon on imaging does not guarantee the patient is pain-free, and vice versa.

At annual review, compare current ultrasound to the prior year's images where available. New or worsening hypoechogenicity in a previously stable tendon deserves closer clinical attention even if VISA scores are unchanged.

When MRI adds value

MRI gives better resolution for partial-thickness tears, insertional bone pathology, and bursal involvement. Reasonable indications for repeat MRI include:

• Inconclusive ultrasound after a clear clinical deterioration
• Need to measure a partial tear before considering surgical referral
• Suspected bone marrow oedema at the tendon insertion (insertional tendinopathy)

Substantial cross-sectional tendon disruption on MRI should prompt orthopedic consultation; the exact threshold used for that referral varies by surgeon and institution and should be set by local practice rather than a single fixed percentage.

Step 4: Injection history and off-label therapy review

A complete injection history is a required part of the annual visit: type, number, timing, and perceived benefit of anything injected in the prior 12 months.

Corticosteroid injections

Corticosteroid injections can provide meaningful short-term pain relief, typically over a matter of weeks, but the tendinopathy literature has repeatedly raised concern that they may be associated with worse outcomes at longer follow-up compared with physiotherapy or a wait-and-see approach, particularly at the lateral epicondyle. At annual review, document:

• Total lifetime corticosteroid injections at the affected tendon
• Time since the last injection
• Any structural change on imaging that could be attributable to steroid exposure

Many clinicians use a general guideline of no more than three lifetime corticosteroid injections at a single tendon site before formally discussing alternatives, though this is a common clinical convention rather than a single universal rule, and should be confirmed against current site-specific guidance.

PRP injections

Platelet-rich plasma (PRP) is autologous blood-derived plasma injected to deliver concentrated growth factors. Evidence is mixed and site-dependent: at least one randomized trial in Achilles tendinopathy found no significant benefit of PRP over saline, while pooled analyses in patellar tendinopathy have suggested a modest benefit over control. These findings come from different trial populations and injection techniques, so results should not be assumed to transfer across tendon sites. At annual review, if PRP was given in the prior year, compare the VISA change from pre-injection baseline against what would plausibly be expected from exercise alone, since exercise-only improvement over similar periods is often substantial.

BPC-157 and peptide protocols

BPC-157 (body protection compound-157) is a synthetic pentadecapeptide originally studied as a gastric-derived protein fragment. Animal studies have reported pro-angiogenic and collagen-related effects in tendon injury models. As of this review, no published randomized controlled trials in humans have established its efficacy or safety for tendinopathy. BPC-157 is not FDA-approved for any indication, and any human use for tendinopathy is off-label and outside established clinical guidelines; some preparations sold for this purpose are compounded or research-grade products whose quality control has not been independently verified here.

Annual review decision framework: what changes the plan

The facts that should change management at a yearly visit are few, and most other findings are context. Use this order of operations.

1. Is there a red flag today? Sudden pop, palpable gap, positive Thompson test, or inability to bear load. If yes, stop the annual-review workflow and get same-day imaging and orthopedic input; everything below waits.
2. Has the VISA/DASH/PRTEE score dropped meaningfully from last year? A drop of roughly 10 points or more is a trigger to reopen the case, not a trigger to add a new injection first. Look for a training-load change, a missed rehab phase, or a new systemic contributor before considering procedures.
3. Has the loading program plateaued for 16 or more weeks? If VISA has not moved despite adherence, the program itself needs restructuring (progression, dosage, or protocol change) before escalating to injections.
4. Is limb symmetry still below about 90 percent, or has the deficit widened? This argues for targeted strengthening, and it is also a reason to delay return-to-sport clearance regardless of how the patient feels subjectively.
5. Has the patient already failed two full 12-week loading cycles with no meaningful VISA gain? This is the point where a genuine discussion of PRP, high-volume or sclerosing injection, or surgical referral (for confirmed structural tears) is reasonable, rather than at 6 weeks of symptoms.
6. Is the patient using PRP or BPC-157? If so, the annual visit is not optional paperwork: confirm informed consent language reflects the actual (limited or absent, respectively) human evidence base, and reconfirm the patient has a defined VISA target and a follow-up interval, not an open-ended trial of the agent.
7. Are metabolic or drug-related contributors unchecked? If TSH, HbA1c, or a lipid panel has not been done recently, or the patient is on a fluoroquinolone or long-term statin, note it and address it as part of this year's plan rather than treating tendinopathy in isolation.

The exception that overrides all of the above: any tendon that suddenly changes character (new instability, sudden loss of strength, a pop) is a same-day evaluation regardless of where the patient sits in this yearly cycle.

Step 5: Red flag screening

Every annual evaluation should include a structured screen for findings that move a patient from conservative management to urgent referral.

Tendon rupture

A complete Achilles rupture typically produces a palpable gap, a positive Thompson test (no plantar flexion when the calf is squeezed with the patient prone), and sudden severe pain, often described as being struck or kicked in the back of the leg. Partial tears can present more subtly. A sudden increase in tendon pain during a single activity, especially with a pop or snap, warrants same-day imaging rather than waiting for the scheduled annual visit.

Metabolic and drug-related contributors

Several systemic factors are recognized in the tendinopathy literature as impairing tendon collagen quality and should be screened at annual review: hypothyroidism, diabetes mellitus, and dyslipidemia. A TSH, HbA1c, and fasting lipid panel are reasonable if not recently done.

The U.S. Food and Drug Administration has issued a boxed warning for fluoroquinolone antibiotics (including ciprofloxacin and levofloxacin) regarding tendinitis and tendon rupture risk, a warning that predates this article and should be confirmed as current on the FDA's drug safety pages before being cited to a patient, since drug safety communications are periodically updated. General information on fluoroquinolone safety communications is available at fda.gov/drugs/drug-safety-and-availability. Statins have also been reported as a pharmacovigilance signal for tendinopathy, though this is an observational association rather than an established causal mechanism confirmed in controlled trials.

Step 6: Return-to-sport and return-to-work readiness

The annual visit is a natural point to formally reassess readiness to return to sport or full occupational duty.

Commonly used clearance criteria

Objective return-to-sport criteria used in sports medicine practice typically require:

• VAS pain below 2/10 during and 24 hours after sport-specific activity
• LSI above roughly 90% on the relevant single-leg test
• A VISA score in the 70s or higher (some clinicians prefer 80 or above for high-demand athletes)
• No reactive spike in pain above 5/10 during loading

Studies in the tendinopathy rehabilitation literature have associated returning to sport before meeting limb-symmetry criteria with a higher rate of re-injury, though the exact magnitude of that risk varies by study and should not be quoted as a single fixed multiplier without checking the source trial.

Occupational tendinopathy

Lateral epicondyle and rotator cuff tendinopathy are the tendon problems most often linked to occupational repetitive strain. For these patients, the annual review should include a functional capacity check relevant to their job (grip strength for lateral epicondyle, shoulder flexion endurance for rotator cuff) and a review of any ergonomic changes made at work. General guidance on managing lateral epicondylalgia supports ergonomic review as part of ongoing conservative management.

Step 7: Setting the next 12-month plan

The final step of the annual evaluation is a documented, patient-specific plan for the coming year, not just a summary of the past one.

A written plan should include:

• A target outcome score for the next review period (for example, moving VISA from the low 60s toward the mid-70s)
• A named loading program with frequency, sets, and reps for the next several weeks
• Explicit criteria for stepping up to injection therapy if the loading program fails
• A defined follow-up interval, typically around 3 months for patients with active symptoms

There is broad agreement across sports medicine literature that exercise-based loading is the foundation of tendinopathy management and that injections and adjunct therapies work best as additions to, not substitutes for, a structured program. A widely referenced clinical caution in this literature is that injecting early, before a loading program has had an adequate trial, may raise long-term recurrence risk without improving outcomes at a year. Specific commentaries and named quotations attributed to individual researchers in earlier drafts of this material could not be independently verified against a checkable source and have been removed rather than presented as direct quotations; readers wanting an authoritative statement of the exercise-first consensus should consult current sports medicine society guidelines directly.

What is established, what is plausible, and what is not established

Established: Progressive tendon loading (eccentric or heavy slow resistance) improves pain and function in Achilles and patellar tendinopathy over a period of weeks to months, in multiple controlled trials. Corticosteroid injection gives faster short-term relief than exercise but carries a recognized signal for worse longer-term outcomes at the lateral epicondyle specifically. Ultrasound and MRI findings do not reliably track with symptoms. Fluoroquinolone antibiotics carry an FDA warning for tendon injury.

Plausible but not settled: The exact numeric recurrence rate for tendinopathy after apparent recovery, the precise VISA-point threshold that should trigger reassessment, and the exact percentage increase in training load that raises injury risk are all reported with varying figures across studies and should be treated as approximate guidance rather than fixed constants.

Not established: BPC-157's efficacy or safety for human tendinopathy has not been demonstrated in published randomized controlled trials; its use remains off-label and experimental. Whether PRP benefit generalizes across tendon sites beyond the specific populations studied is not established.

Annual evaluation summary table